Effect of high-flow nasal cannula oxygen versus standard oxygen on mortality in patients with acute hypoxaemic respiratory failure: protocol for a multicentre, randomised controlled trial (SOHO)
Authors:
- Jean-Pierre FratJFJean-Pierre Frat
- Remi CoudroyRCRemi Coudroy
- Jean-Pierre QuenotJQJean-Pierre Quenot
- Christophe GuittonCGChristophe Guitton
- Julio BadieJBJulio Badie
- Arnaud GacouinAGArnaud Gacouin
- Stephan EhrmannSEStephan Ehrmann
- Alexandre DemouleADAlexandre Demoule
- Fabien JarousseauFJFabien Jarousseau
- Guillaume CarteauxGCGuillaume Carteaux
- Jean Philippe RigaudJRJean Philippe Rigaud
- Jean ReignierJRJean Reignier
Open Access
Abstract
Introduction First-line oxygenation strategy in patients with acute hypoxaemic respiratory failure consists in standard oxygen or high-flow nasal oxygen therapy. Clinical practice guidelines suggest the use of high-flow nasal oxygen rather than standard oxygen. However, findings remain contradictory with a low level of certainty. We hypothesise that compared with standard oxygen, high-flow nasal oxygen may reduce mortality in patients with acute hypoxaemic respiratory failure. Method and analysis The Standard Oxygen versus High-flow nasal Oxygen-trial is an investigator-initiated, multicentre, open-label, randomised controlled trial comparing high-flow nasal oxygen versus standard oxygen in patients admitted to an intensive care unit (ICU) for acute respiratory failure with moderate-to-severe hypoxaemia. 1110 patients will be randomly assigned to one of the two groups with a ratio of 1:1. The primary outcome is the number of patients who died 28 days after randomisation. Secondary outcomes include comfort, dyspnoea and oxygenation 1 hour after treatment initiation, the number of patients intubated at day 28, mortality in ICU, in hospital and until day 90, and complications during ICU stay. Ethics and dissemination The study has been approved by the central Ethics Committee ‘Sud Méditerranée III’ (2020-07-05) and patients will be included after informed consent. The results will be submitted for publication in peer-reviewed journals. Trial registration number NCT04468126.Keywords
Funding Information
- Ministère des Affaires Sociales et de la Santé (PHRC-19-0305)
- Fisher and Paykel Healthcare (contribution to financing the study)
This publication has 29 references indexed in Scilit:
- High-Flow Nasal Cannula Oxygenation in Immunocompromised Patients With Acute Hypoxemic Respiratory Failure: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique StudyCritical Care Medicine, 2017
- Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory FailureAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trialThe Lancet Respiratory Medicine, 2016
- Failure of Noninvasive Ventilation for De Novo Acute Hypoxemic Respiratory FailureCritical Care Medicine, 2016
- Nasal high flow clears anatomical dead space in upper airway modelsJournal of Applied Physiology, 2015
- High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory FailureNew England Journal of Medicine, 2015
- Outcomes for Patients With Cancer Admitted to the ICU Requiring Ventilatory SupportChest, 2014
- Performance of oxygen delivery devices when the breathing pattern of respiratory failure is simulated*Anaesthesia, 2008
- Physiologic Effects of Noninvasive Ventilation during Acute Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Treatment of Acute Hypoxemic Nonhypercapnic Respiratory Insufficiency With Continuous Positive Airway Pressure Delivered by a Face MaskJAMA, 2000